Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, R Thomas G, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-Smith GL; Australian and New Zealand Inflammatory Bowel Disease Consortium. Doecke JD, et al. Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. doi: 10.1111/apt.13880. Epub 2016 Dec 19. Aliment Pharmacol Ther. 2017. PMID: 27995633
Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease.
Krishnaprasad K, Walsh A, Begun J, Bell S, Carter D, Grafton R, Sechi A, Sewell K, McMahon A, Connor S, Radford-Smith G, Andrews JM; Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC) and Crohn’s Colitis Cure (CCC). Krishnaprasad K, et al. Scand J Gastroenterol. 2020 Dec;55(12):1419-1426. doi: 10.1080/00365521.2020.1839960. Epub 2020 Nov 8. Scand J Gastroenterol. 2020. PMID: 33161791
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
Fleischmann RM, Alten R, Pileckyte M, Lobello K, Hua SY, Cronenberger C, Alvarez D, Bock AE, Sewell KL. Fleischmann RM, et al. Among authors: sewell kl. Arthritis Res Ther. 2018 Aug 15;20(1):178. doi: 10.1186/s13075-018-1676-y. Arthritis Res Ther. 2018. PMID: 30111357 Free PMC article. Clinical Trial.
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, Palaparthy R, Schumacher K, Schmitt S, Hua SY, Ianos C, Sewell KL. Cohen SB, et al. Among authors: sewell kl. Arthritis Res Ther. 2018 Jul 27;20(1):155. doi: 10.1186/s13075-018-1646-4. Arthritis Res Ther. 2018. PMID: 30053896 Free PMC article. Clinical Trial.
36 results